• Explore /
  • Poster
  • / Prognostic value of the lung immune prognostic index in patients with untreated advanced renal cell carcinoma (aRCC) receiving nivolumab plus ipilimumab (N+I) or sunitinib (SUN) in the CheckMate 214 trial.

Prognostic value of the lung immune prognostic index in patients with untreated advanced renal cell carcinoma (aRCC) receiving nivolumab plus ipilimumab (N+I) or sunitinib (SUN) in the CheckMate 214 trial.

Abstract Video & Slides Poster

Authors

null

Lucia Carril-Ajuria

Gustave Roussy, Villejuif, France

Lucia Carril-Ajuria , Robert J. Motzer , Nizar M. Tannir , David F. McDermott , Hans J. Hammers , Frede Donskov , Brian I. Rini , Ruiyun Jiang , Chung-Wei Lee , Heshani Desilva , Laurence Albiges , Elizabeth R. Plimack

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT02231749

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 4538)

DOI

10.1200/JCO.2022.40.16_suppl.4538

Abstract #

4538

Poster Bd #

29

Abstract Disclosures

Similar Posters

First Author: Nizar M. Tannir

First Author: David F. McDermott

First Author: Charlene Mantia

Poster

2022 ASCO Genitourinary Cancers Symposium

Assessing physician prescribing behaviors in first-line (1L) advanced renal cell carcinoma (aRCC): A case-based study.

Assessing physician prescribing behaviors in first-line (1L) advanced renal cell carcinoma (aRCC): A case-based study.

First Author: Ajeet Gajra